1. R. Macarron, M. N. Banks, D. Bojanic, D. J. Burns, D. A. Cirovic, T. Garyantes, D. V. S. Green, R. P. Hertzberg, W. P. Janzen, J. W. Paslay, U. Schopfer, G. S. Sittampalam, Impact of high-througput screening in biomedical research. Nat. Rev. Drug Discov., 2011, 10, 188-195.
2. D. C. Swinney, J. Anthony, How were new medicines discovered? Nat. Rev. Drug Discov., 2011, 10, 507-519.
3. A. L. Hopkins, C. R. groom, The druggable genome. Nat. Rev. Drug Discov. 2002, 1, 727-730.
4. U. E. Mariinenez-Outschoorn, M. Peiris-Pagés, R. G. Pestell, F. Sotgia, M. P. Lisanti, Cancer metabolism: a therapeutic perspective. Nat. Rev. Clin. Oncol., 2017, 14, 11-31.
5. M. G. Vander Heiden, Targeting cancer metabolism: a therapeutic window opens. Nat. Rev. Drug Discov., 2011, 10, 671-684.
6. L. Galluzzi. O. Kepp, M. G. Vander Heiden, G. Kroemer, Metabolic targets for cancer therapy. Nat. Rev. Drug Discov., 2013, 12, 829-846.
7. A. Saghatelian, B. F. Cravatt, Assignment of protein function in the postgenomic era. Nat. Chem. Biol., 2005, 1, 130-142.
8. T. Komatsu, Y. Urano, Chemical Toolbox for "Live" Biochemistry to Understand Enzymatic Functions in Living Systems. J. Biochem., 2019, 0, 1-11.
9. G. Dong, Q. Mao, W. Xia, Y. Xu, J. Wang, L. Xu, F. Jiang, PKM2 and cancer: The function of PKM2 beyond glycolysis. Oncology Letters, 2016, 11, 1980-1986.
10. B. Chaneton, P. Hillmann, L. Zheng, A. C. L. Martin, O. D. K. Maddocks, A. Chokkathukalam, J. E. Coyle, A. Jankevics, F. P. Holding, K. H. Vousden, C. Frezza, M. O’Reilly, E. Gottlieb, Serine is a natural ligand and allosteric activator of pyruvate kinase M2. Nature, 2012, 491, 458-462.
11. M. Kawaguchi, T. Okabe, S. Okudaira, K. Hanaoka, Y. Fujikawa, T. Terai, T. Komatsu, H. Kojima, J. Aoki, T. Nagano, Fluorescence Probe for Lysophospholipase C/NPP6 Activity and a Potent NPP6 Inhibitor. J. Am. Chem. Soc., 2011, 133, 12021-12030.
12. M. N. Levine, R. T. Raines, Trimethyl lock: a trigger for molecular release in chemistry, biology, and pharmacology. Chem. Sci., 2012, 3, 2412-2420.
13. K. Setsukinai, Y. Urano, K. Kakinuma, H. J. Majima, T. Nagano, Development of Novel Fluorescence Probes That Can Reliably Detect Reactive Oxygen Species and Distinguish Specific Species. J. Biol. Cem., 2003, 278, 3170-3175.
14. N. Rabbani, M. Xue, P. J. Thornalley, Activity, regulation, copy number and function in the glyoxalase system. Biochem. Soc. Trans., 2014, 42, 419-424.
15. P. J. Thornalley, N. Rabbani, Glyoxalase in tumourigenesis and multidrug resistance. Semin. Cell Dev. Biol., 2011, 22, 318-325.
16. N. Rabbani, M. Xue, P. J. Thornalley, Methylglyoxal-induced dicarbonyl stress in aging and disiease: first steps towards glyoxalase 1-based treatments. Clin. Sci., 2016, 130, 1677-1696.
17. F. Hosoda, Y. Arai, N. Okada, H. Shimizu, M. Miyamoto, N. Kitagawa, H. Katai, H. Taniguchi, K. Yanagihara, I. Imoto, J. Inazawa, M. Ohki, T. Shibata, Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer. Oncogene, 2015, 34, 1196-1206.
18. Hai-Tao Peng, J. Chen, Tian-Yu Liu, Yan-Qing Wu, Xiao-Hong Lin, Yuan-Hui Lai, Ying-Feng Huang, Up-regulation of the tumor promoter Glyoxalase-1 indicates poor prognosis in breast cancer. Int. J. Clin. Exp. Pathol., 2017, 10, 10852-10862.
19. W. Bair, C. Cabello, K. Uchida, A. Bause, G. Wondrak, GLO1 overexpression in human malignant melanoma. Melanoma Res., 2010, 20, 85-96.
20. S. Zhang, X. Liang, X. Zheng, H. Huang, X. Chen, K. Wu, B. Wang, S. Ma. Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma. Int. J. Clin. Exp. Pathol., 2014, 7, 2079-2090.
21. H. Sakamoto, T. Mashima, S. Sato, Y. Hashimoto, T. Yamori, T. Tsuruo, Selective Activation of Apoptosis Program by S-p-bromobenzylglutathione Cyclopentyl Diester in Glyoxalase I-overexpressing Human Lung Cancer Cells. Clin. Cancer Res. 2001, 7, 2513-2518.
22. H. Sakamoto, T. Mashima, A. Kizaki, S. Dan, Y. Hashimoto, M. Naito, T. Tsuruo, Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood, 2000, 95, 3214-3218.
23. M. Takeuchi, S. Kimura, J. Kuroda, E. Ashihara, M. Kawatani, H. Osada, K. Umezawa, E. Yasui, M. Imoto, T. Tsuruo, A. Yokota, R. Tanaka, R. Nagao, T. Nakahata, Y. Fujiyama, T. Maekawa, Glyoxalase-I is a novel target against Bcr- Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment. Cell Death Differ., 2010, 17, 1211-1220.
24. B. Chiavarina, Marie-Julie Nokin, F. Durieux, E. Bianchi, A. Turtoi, O. Peulen, P. Peixoto, P. Irigaray, K. Uchida, D. Belpomme, P. Delvenne, V. Castronovo, A. Bellahcène, Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes. Oncotarget, 2012, 5, 5472-5482.
25. Y. Wang, Y. Kuramitsu, T. Ueno, N. Suzuki, S. Yoshino, N. Iizuka, J. Akada, T. Kitagawa, M. Oka, K. Nakamura, Glyoxalase I (GLO1) is Up-regulated in Pancreatic Cancerous Tissues Compared with Related Non-cancerous Tissues. Anticancer Res., 2012, 32, 3219-3222.
26. A. F. Gazdar, P. A. Bunn, J. D. Minna, Small-cell lung cancer: what we know, what we need to know and the path forward. Nat. Rev. Cancer, 2017, 17, 725- 737.
27. W. H. Habig, M. J. Pabst, W. B. Jakoby, Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem., 1974, 249, 7130- 7139.
28. M. J. Lukey, W. P. Katt, R. A. Cerione, Targeting amino acid metabolism for cancer therapy. Drug Discov. Today, 2017, 22, 796–804.
29. J. Zhang, N. N. Pavlova, C. B. Thompson, Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J., 2017, 36, 1302-1315.
30. B. J. Altman, Z. E. Stine, C. V. Dang, From Krebs to clinic: glutamine metabolism to cancer therapy. Nat. Rev. Cancer, 2016, 16, 619-634.
31. N. Vié, V. Copois, C. Bascoul-Mollevi, V. Denis, N. Bec, B. Robert, C. Fraslon, E. Conseiller, F. Molina, C. Larroque, P. Martineau, M. D. Rio, C. Gongora, Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells. Mol. Cancer, 2008, 7, 14.
32. W. C. Zhang, N. Shyh-Chang, H. Yang, A. Rai, S. Umashankar, S. Ma, B. S. Soh, L. L. Sun, B. C. Tai, M. E. Nga, K. K. Bhakoo, S. R. Jayapal, M. Nichane, Q. Yu, D. A. Ahmed, C. Tan, W. P. Sing, J. Tam, A. Thirugananam, M. S. Noghabi, Y. H. Pang, H. S. Ang, W. Mitchell, P. Robson, P. Kaldis, R. A. Soo, S. Swarup, E. H. Lim, B. Lim, Glycine Decarboxylase Activity Drives Non-Small Cell Lung Cancer Tumor-Initiating Cells and Tumorigenesis. Cell, 2012, 148, 259-272.
33. B. Zhang, J. Tornmalm, J. Widengren, H. Vakifahmetoglu-Norberg, E. Norberg, Characterization of the Role of the Malate Dehydrogenases to Lung Tumor Cell Survival. J. Cancer, 2017, 8, 2088-2096.
34. S. Atlante, A. Visintin, E. Marini, M. Savoia, C. Dianzani, M. Giorgis, D. Sürün, F. Maione, F. Schnütgen, A. Farsetti, A. M. Zeiher, M. Bertinaria, E. Giraudo,F. Spallotta, C. Cencioni, C. Gaetano, α-ketoglutarate dehydrogenase inhibition counteracts breast cancer-associated lung metastasis. Cell Death and Disease, 2018, 9, 756.
35. C. Sakai, E. Tomitsuka, H. Esumi, S. Harada, K. Kita, Mitochondrial fumarate reductase as a target of chemotherapy: from parasites to cancer cells. Biochim. Biophys. Acta, 2012, 1820, 643-651.
36. R. Kumar, L. Coronel, B. Somalanka, A. Raju, O. A. Aning, O. An, Y. S. Ho, S. Chen, S. Y. Mak, P. Y. Hor, H. Yang, M. Lakshmanan, H. Itoh, S. Y. Tan, Y. K. Lim, A. P. C. Wong, S. H. Chew, T. H. Huynh, B. C. Goh, C. Y. Lim, V. Tergaonkar, C. F. Cheok, Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53- defective cancers. Nat. commun., 2018, 9, 3931.
37. D. Strumberg, B. Schulthesis, Regorafenib for cancer. Expert Opin. Investig. Drugs, 2012, 21, 879-889.
38. L. Adnane, P. A. Trail, I. Taylor, S. M. Wilhelm, Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature. Methods Enzymol., 2006, 407, 597-612.
39. NIH National Cancer Institute (https://www.cancer.gov/)
40. Jae-Seon Lee, J. H. Kang, Seon-Hyeong Lee, Chang-Hun Lee, J. Son, Soo-Youl Kim, Glutaminase 1 inhibition reduces thymidine synthesis in NSCLC. Biochem. Biophys. Res. Commun., 2016, 477, 374-382.
41. K. Thangavelua, C. Q. Pana, T. Karlbergc, G. Balajid, M. Uttamchandania, V. Sureshd, H. Schülerc, B. C. Lowa, J. Sivaramana, Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism. Proc. Natl. Acad. Sci. USA, 2012, 109, 7705-7710.
42. Chun-Nan Yeh, Yu-Chan Chang, Y. Su, D. Shin-Shian Hsu, Chi-Tung Cheng, Ren-Chin Wu5, Yi-Hsiu Chung, Kun-Chun Chiang, Ta-Sen Yeh, Meng-Lun Lu, Chun-Yu Liu, P. Mu-Hsin Chang, Ming-Han Chen, Chi-Ying F. Huang, Mi. Hsiao, Ming-Huang Chen, Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients Oncotarget, 2017, 8, 113444-113459.
43. K. W. Yip, X. Mao, P. Y. B. Au, D. W. Hedley, S. Chow, S. Dalili, J. D. Mocanu, C. Bastianutto, A. Schimmer, Fei-Fei Liu, Benzethonium Chloride: A Novel Anticancer Agent Identified by Using a Cell-Based Small-Molecule Screen. Clin. Cancer Res., 2006, 12, 5557-5569.
44. T. Tamaki, Y. Dong, Y. Ohno, T. Sobue, H. Nishimoto, A. Shibata, The burden of rare cancer in Japan: Application of theRARECARE definition. Cancer Epidemiology, 2014, 38, 490–495.
45. R. K. Pillai, K. Jayasree, Rare cancers: Challenges & issues, Indian J. Med. Res., 2017, 145, 17–27.
46. W. H. Melhuish, A standard fluorescence spectrum for calibrating spectro- fluorophotometers. J. Phys. Chem., 1960, 64, 762-764.
47. Y. Urano, M. Kamiya, K. Kanda, T. Ueno, K. Hirose, T. Nagano, Evolution of Fluorescein as a Platform for Finely Tunable Fluorescence Probes. J. Am. Chem. Soc., 2005, 127, 4888-4894.